Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Breccia

Showing results (61-70 of 427) with videos related to

Pageof 43
Sort By:
Expert Opinion on Pharmacotherapy|July 4, 2014
Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacyMassimo Breccia, Matteo Molica, Irene Zacheo, et al.
Future Oncology (London, England)|February 12, 2025
Asciminib in the treatment of chronic myeloid leukemia in chronic phaseAlessandro Costa, Emilia Scalzulli, Maria Laura Bisegna, et al.
Cancers|October 13, 2021
Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future ScenariosFrancesca Palandri, Massimo Breccia, Valerio De Stefano, et al.
Frontiers in Oncology|April 2, 2021
Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic PhaseFausto Castagnetti, Fabrizio Pane, Gianantonio Rosti, et al.
Expert Review of Hematology|February 8, 2021
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsFabio Efficace, Marco Vignetti, Francesco Sparano, et al.
International Journal of Hematology|August 5, 2022
Asciminib as a third line option in chronic myeloid leukemiaAlessandro Laganà, Emilia Scalzulli, Ida Carmosino, et al.
Frontiers in Oncology|March 29, 2021
Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid LeukemiaMassimo Breccia, Elisabetta Abruzzese, Mario Annunziata, et al.
Current Cancer Drug Targets|June 15, 2022
Future Management of Chronic Myeloid Leukemia: From Dose Optimization to New AgentsMassimo Breccia, Emilia Scalzulli, Sara Pepe, et al.
Best Practice & Research. Clinical Haematology|November 1, 2003
Diagnostic value of detecting fusion proteins derived from chromosome translocations in acute leukaemiaFrancesco Lo-Coco, Massimo Breccia, Nélida Noguera, et al.
Annals of Hematology|October 12, 2014
Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatmentMassimo Breccia, Matteo Molica, Irene Zacheo, et al.
Pageof 43

Showing results (61-70 of 427) with videos related to

Sort By:
Pageof 43
Expert Opinion on Pharmacotherapy|July 4, 2014
Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacyMassimo Breccia, Matteo Molica, Irene Zacheo, et al.
Future Oncology (London, England)|February 12, 2025
Asciminib in the treatment of chronic myeloid leukemia in chronic phaseAlessandro Costa, Emilia Scalzulli, Maria Laura Bisegna, et al.
Cancers|October 13, 2021
Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future ScenariosFrancesca Palandri, Massimo Breccia, Valerio De Stefano, et al.
Frontiers in Oncology|April 2, 2021
Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic PhaseFausto Castagnetti, Fabrizio Pane, Gianantonio Rosti, et al.
Expert Review of Hematology|February 8, 2021
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsFabio Efficace, Marco Vignetti, Francesco Sparano, et al.
International Journal of Hematology|August 5, 2022
Asciminib as a third line option in chronic myeloid leukemiaAlessandro Laganà, Emilia Scalzulli, Ida Carmosino, et al.
Frontiers in Oncology|March 29, 2021
Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid LeukemiaMassimo Breccia, Elisabetta Abruzzese, Mario Annunziata, et al.
Current Cancer Drug Targets|June 15, 2022
Future Management of Chronic Myeloid Leukemia: From Dose Optimization to New AgentsMassimo Breccia, Emilia Scalzulli, Sara Pepe, et al.
Best Practice & Research. Clinical Haematology|November 1, 2003
Diagnostic value of detecting fusion proteins derived from chromosome translocations in acute leukaemiaFrancesco Lo-Coco, Massimo Breccia, Nélida Noguera, et al.
Annals of Hematology|October 12, 2014
Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatmentMassimo Breccia, Matteo Molica, Irene Zacheo, et al.
Pageof 43